Treatment with immune checkpoint inhibitors (ICIs) directed against the PD‐1/PD‐L1 axis has revolutionized cancer treatment, especially achieving substantial success in the management of patients with advanced non‐small cell lung cancer (NSCLC).1 Here, CD274 is linked to lung cancer.